High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatment

Sims, E.K., Geyer, S.M., Long, S.A., Herold, K.C. (2023). High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatment. https://doi.org/10.1007/s00125-023-06003-5

Sims, Emily K., et al.. "High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatment". CrossRef, 2023. doi:10.1007/s00125-023-06003-5.

@article{sims2023, author = {Emily K. Sims and Susan M. Geyer and S. Alice Long and Kevan C. Herold}, title = {High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatment}, year = {2023}, journal = {CrossRef}, doi = {10.1007/s00125-023-06003-5}, url = {https://doi.org/10.1007/s00125-023-06003-5}, }

High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatment

Penulis (4)

Format Sitasi

Akses Cepat